Abstract: Known since antiquity, tuberculosis remains a major public health challenge throughout the world despite the availability of therapeutic interventions. The long treatment times of existing drugs along with the emergence of resistant variations have led researchers to seek new drugs. This seminar will describe ongoing projects to contribute to this goal, including the study of new b-lactam antitubercular agents and inhibitors of the TB phosphopantetheinyl transferase, a newly validated target. 

References

[1] Ballinger et al., Science, 2019, 363, eeau8959.

[2] Ottavi et al., J. Med. Chem., 2022, 65, 1996–2022.

[3] Ottavi et al., ACS Med. Chem. Lett., 2023, 14, 970–976.